FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914887566> ?p ?o ?g. }

• W2914887566 endingPage "68" @default.
• W2914887566 startingPage "59" @default.
• W2914887566 abstract "Inhibitory receptors CTLA-4 and PD-1 (immune checkpoints) play a key role in regulation of immune reactions. They suppress excessive immune response against pathogenic microbes and prevent autoimmune reactions. The immune checkpoints are targets of the modern effective therapy based on human and humanized monoclonal antibodies (ipilimumab and nivolumab, tremelimumab, pembrolizumab, etc). However, despite its high efficiency compared to standard chemotherapy, the therapy based on blocking immune check points is facing several problems, i.e., high therapy cost and severe negative autoimmune-related side effects. Unfortunately, this therapy helps to minority of the patients. Hence, further studies are required to improve its efficiency and safety, as well as to search for selection criteria of the patients who would benefit from the therapy. An appealing approach to reduce negative side effects from immune checkpoint inhibition is application of the blocking antibodies, aiming for ex vivo generation of patients’ activated immune cells for cancer therapy, thus avoiding systemic drug administration. Our aim was to elucidate influence of immune checkpoint blocking antibodies on the expression of CTLA-4 and PD-1 in such an in vitro model. First of all, we have determined quantities of lymphocyte receptors in peripheral blood of healthy volunteers, or cancer patients with disseminated melanoma. Moreover, we defined effect from the addition of antibodies against immune checkpoints on proportions of cells expressing CTLA-4 and PD-1 in the population of phytohemagglutininactivated lymphocytes. Our study demonstrated that, in presence of antibodies to either of the two checkpoints during in vitro cell activation, the blockade of specific target receptor is accompanied by reduced number of cells positive for another checkpoint. Hence, the antibodies directed against PD-1 or CTLA-4 seem to suppress both negative signal cascades at once, if tested under such experimental conditions. Noteworthy, the response to blocking antibodies for different immune checkpoints varied for different donors. Our data may be used for development of effective combinations of lymphocyte activators and immune check-point inhibitors, for in vitro generation of activated lymphocytes applied for adoptive cancer therapy, as well as for prediction of possible responses to antibodies against CTLA-4 or PD-1, aiming to select the best personalized cancer immunotherapy." @default.
• W2914887566 created "2019-02-21" @default.
• W2914887566 creator A5003067259 @default.
• W2914887566 creator A5046234002 @default.
• W2914887566 creator A5070657172 @default.
• W2914887566 creator A5076661488 @default.
• W2914887566 creator A5086009175 @default.
• W2914887566 date "2019-01-24" @default.
• W2914887566 modified "2023-10-05" @default.
• W2914887566 title "INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS" @default.
• W2914887566 cites W1516446271 @default.
• W2914887566 cites W1534815147 @default.
• W2914887566 cites W1791759367 @default.
• W2914887566 cites W1849671624 @default.
• W2914887566 cites W1915698186 @default.
• W2914887566 cites W1936513833 @default.
• W2914887566 cites W1975992327 @default.
• W2914887566 cites W2023606978 @default.
• W2914887566 cites W2048073154 @default.
• W2914887566 cites W2060451389 @default.
• W2914887566 cites W2073776582 @default.
• W2914887566 cites W2076067786 @default.
• W2914887566 cites W2087482409 @default.
• W2914887566 cites W2088313410 @default.
• W2914887566 cites W2094991897 @default.
• W2914887566 cites W2100992652 @default.
• W2914887566 cites W2101094698 @default.
• W2914887566 cites W2104764745 @default.
• W2914887566 cites W2140419562 @default.
• W2914887566 cites W2143163879 @default.
• W2914887566 cites W2147579197 @default.
• W2914887566 cites W2155464214 @default.
• W2914887566 cites W2159783687 @default.
• W2914887566 cites W2166662937 @default.
• W2914887566 cites W2202949009 @default.
• W2914887566 cites W2296403803 @default.
• W2914887566 cites W2317170392 @default.
• W2914887566 cites W2336076245 @default.
• W2914887566 cites W2462014591 @default.
• W2914887566 cites W2619966018 @default.
• W2914887566 cites W2730495418 @default.
• W2914887566 cites W2752227448 @default.
• W2914887566 doi "https://doi.org/10.15789/1563-0625-2019-1-59-68" @default.
• W2914887566 hasPublicationYear "2019" @default.
• W2914887566 type Work @default.
• W2914887566 sameAs 2914887566 @default.
• W2914887566 citedByCount "1" @default.
• W2914887566 countsByYear W29148875662023 @default.
• W2914887566 crossrefType "journal-article" @default.
• W2914887566 hasAuthorship W2914887566A5003067259 @default.
• W2914887566 hasAuthorship W2914887566A5046234002 @default.
• W2914887566 hasAuthorship W2914887566A5070657172 @default.
• W2914887566 hasAuthorship W2914887566A5076661488 @default.
• W2914887566 hasAuthorship W2914887566A5086009175 @default.
• W2914887566 hasBestOaLocation W29148875661 @default.
• W2914887566 hasConcept C121608353 @default.
• W2914887566 hasConcept C126322002 @default.
• W2914887566 hasConcept C159654299 @default.
• W2914887566 hasConcept C203014093 @default.
• W2914887566 hasConcept C21705690 @default.
• W2914887566 hasConcept C2776090121 @default.
• W2914887566 hasConcept C2777701055 @default.
• W2914887566 hasConcept C2778650287 @default.
• W2914887566 hasConcept C2780030458 @default.
• W2914887566 hasConcept C2780057760 @default.
• W2914887566 hasConcept C2780674031 @default.
• W2914887566 hasConcept C2780851360 @default.
• W2914887566 hasConcept C2781433595 @default.
• W2914887566 hasConcept C45121317 @default.
• W2914887566 hasConcept C502942594 @default.
• W2914887566 hasConcept C542903549 @default.
• W2914887566 hasConcept C71924100 @default.
• W2914887566 hasConcept C8891405 @default.
• W2914887566 hasConceptScore W2914887566C121608353 @default.
• W2914887566 hasConceptScore W2914887566C126322002 @default.
• W2914887566 hasConceptScore W2914887566C159654299 @default.
• W2914887566 hasConceptScore W2914887566C203014093 @default.
• W2914887566 hasConceptScore W2914887566C21705690 @default.
• W2914887566 hasConceptScore W2914887566C2776090121 @default.
• W2914887566 hasConceptScore W2914887566C2777701055 @default.
• W2914887566 hasConceptScore W2914887566C2778650287 @default.
• W2914887566 hasConceptScore W2914887566C2780030458 @default.
• W2914887566 hasConceptScore W2914887566C2780057760 @default.
• W2914887566 hasConceptScore W2914887566C2780674031 @default.
• W2914887566 hasConceptScore W2914887566C2780851360 @default.
• W2914887566 hasConceptScore W2914887566C2781433595 @default.
• W2914887566 hasConceptScore W2914887566C45121317 @default.
• W2914887566 hasConceptScore W2914887566C502942594 @default.
• W2914887566 hasConceptScore W2914887566C542903549 @default.
• W2914887566 hasConceptScore W2914887566C71924100 @default.
• W2914887566 hasConceptScore W2914887566C8891405 @default.
• W2914887566 hasIssue "1" @default.
• W2914887566 hasLocation W29148875661 @default.
• W2914887566 hasLocation W29148875662 @default.
• W2914887566 hasOpenAccess W2914887566 @default.
• W2914887566 hasPrimaryLocation W29148875661 @default.
• W2914887566 hasRelatedWork W1587414944 @default.
• W2914887566 hasRelatedWork W2285109017 @default.

• next